Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch table for July 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during July 2014.

For an indepth analysis of these deals, read 'Pharma deals during July 2014'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

Shire/  AbbVie
Company acquisition (tax inversion)
Product portfolio - neuroscience, rare diseases, gastrointestinal, internal medicine
54,000
Abbott/ Mylan
Asset acquisition (tax inversion)
Ex-US developed markets specialty and branded generics business * 5,300
Rottapharm/ Meda
Company acquisition   
Portfolio of Rx and consumer products
3,080
Cosmo Technologies/ Salix Pharmaceuticals
Merger (tax inversion)   
Portfolio of treatments for gastrointestinal disease and disorders
2,700
Almirall/ AstraZeneca
Asset acquisition
Respiratory business including various respiratory assets and device capabilities
2,095
Seragon Pharmaceuticals/ Genentech
Company acquisition   
Selective Estrogen Receptor Degrader (SERD) platform for hormone dependent breast cancer, inc ARN-810 (p1)
1,725
Baxter Bioscience/ Pfizer
Asset acquisition
Vaccine business and production facilities
635
Zealand Pharma/ Boehringer Ingelheim
R&D collaboration
Peptide discovery collaboration with cardio-metabolic focus
395
InnoPharma/ Pfizer
Company acquisition
Portfolio of generic FDA approved products and injectable and ophthalmic products under development   
360
Sigma-Tau/ Jazz Pharmaceuticals
Regaining rights **
Defibrotide for severe hepatic veno-occlusive disease (approved EU/ NDA US)   
250
ArmaGen/ Shire   
Licence, collaboration   
AGT-182, enzyme replacement therapy for  Hunter syndrome (preclinical)
225
CureVac/ Sanofi Pasteur
Exercise of option,  licence
RNActive vaccine technology vs undisclosed pathogens (preclinical)
202+
Aciex Therapeutics/ NicOx
Company acquisition
Portfolio of ophthalmic products, inc AC-170  for allergic conjunctivitis (p3)   
120
Anacor Pharmaceuticals/  PharmaDerm (Sandoz)
Licence†
Kerydin topical for toenail onychomycosis (approved)   
110
AmorChem/ Roche
Discovery collaboration, option to license
Small molecule therapy for myotonic muscular dystrophy 1 (discovery)
107
UCB/ Dermira
Licence ††
Cimzia (certolizumab pegol) - drug repurposing (p2 for psoriasis)
89.5 + 20 equity
Codexis/ GSK
Licence
CodeEvolver protein engineering technology (platform)   
63.5+
Supernus Pharmaceutical/  HealthCare Royalty Partners
Royalty/milestone monetisationCertain royalty /milestone rights to Orenitram (treprostinil) extended-release tablets  (marketed)
30
Immunocore/ Eli Lilly
Co-discovery /co-development, options (cost/profit share)
ImmTAC (Immune mobilising mTCR Against Cancer) technology (discovery)   
25+

Noven Therapeutics/  ANI Pharmaceuticals
Acquisition of NDA †
Lithobid (lithium carbonate extended release  tablets) for manic-depressive illness (NDA)
12

All deals are worldwide unless otherwise noted.
*    Europe, Japan, Canada, Australia and New Zealand
**  US + all other countries in the Americas
†    US
††     Exclusive licence to develop for psoriasis in N. America, EU; licence to market N. America to dermatologists

The Deal Watch table is compiled by Medius Associates

12th August 2014

The Deal Watch table is compiled by Medius Associates

12th August 2014

From: Research, Sales

Share

Tags


Career advice

No results were found

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Infographics